Canadian biotech company SemBioSys Genetics is exploring its strategic alternatives, including a corporate sale or merger, a strategic transaction for either insulin or Apo, an asset sale, a significant restructuring and recapitalization or a wind down of the company's operations. According to a release, the company has already laid off an unspecified number of employees. SemBioSys has been using patented plant seed, oil body and expression technology platforms to develop biosimilar drug candidates and proteins. SemBioSys release